Cost-efficacy in interventional cardiology; results from the EPISTENT study. Evaluation of Platelet IIb/IIIa Inhibitor For Stenting Trial.
Redirect to publisher's version
(publisher's version.url.txt, 40 bytes)
AIMS: The EPISTENT study has demonstrated that the combined use of abciximab and stenting as an adjunct to PTCA leads to increased event-free survival compared to either using abciximab or stenting alone. However, this combined strategy may be costly and the additional costs have to be weighted against the additional effects. METHOD AND RESULTS: The 6-months efficacy data from the EPISTENT study are combined with Dutch estimates of unit costs. Adding a stent to a procedure with abciximab further decreases the number of revascularizations at an extra cost of Euros 12,000 (95% upper limit (u.l.) Euros 31,000) per additional major adverse cardiac event-free survivor. Adding abciximab to a stenting procedure decreases the incidence of myocardial infarctions at an extra cost of Euros 13,000 (95% u.l. Euros 27,000) per additional myocardial infarction-free survivor. In the subgroup of diabetics, adding abciximab improves revascularization rates as well, resulting in a cost-efficacy rate of Euros 2000 (95% u.l. Euros 25,000) per additional MACE-free survivor, with uncertainty regions indicating potential costs savings. CONCLUSION: The combination of stenting and abciximab costs about Euros 13,000 to avoid one event after PTCA. In diabetic patients the strategy may be cost-saving.
- Risk Factors
- Cost-Benefit Analysis
- Combined Modality Therapy
- Middle Aged
- Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors
- Myocardial Infarction/*economics/mortality/therapy
- Antibodies, Monoclonal/*economics/therapeutic use
- Anticoagulants/*economics/therapeutic use
- Immunoglobulin Fab Fragments/*economics/therapeutic use
- Platelet Aggregation Inhibitors/*economics/therapeutic use